Genetic screening technology (PGT) has become a core component of assisted reproductive and in vitro fertilization treatment in Kyrgyzstan.
Through this technology, doctors can screen for potential genetic defects before embryo implantation, ensuring the health of newborns from the source.
The Tulip International Reproductive Center not only introduces cutting-edge sequencing equipment from around the world, but also has an experienced team of genetic experts dedicated to helping every family achieve eugenics.
Q1: What is Genetic Screening (PGT)? How does it 'read' embryo health?
PGT， Pre implantation genetic testing, commonly known as "third-generation IVF". Its working principle is to perform a "physical examination" of the embryo's DNA before transferring it to the uterus.
Operation timing: Usually carried out during the blastocyst stage of the fertilized egg development to the 5th to 7th day.
Sampling method: Embryologists will use sophisticated microscopic techniques to extract 3-5 cells from the trophoblast layer of the blastocyst (the part that will develop into the placenta in the future). This process avoids the inner cell mass (the part that will develop into a fetus in the future), so it will not damage the embryo itself.
Testing content:
Chromosome aneuploidy screening (PGT-A): Check whether the number of 23 pairs of chromosomes is normal, whether there is an increase or loss (such as trisomy 21 syndrome).
Single gene disease testing (PGT-M): for parents known to carry specific pathogenic genes, testing whether the embryo has inherited the pathogenic mutation (such as thalassemia, hemophilia).
Q2: The core advantage of genetic screening: why can it improve the success rate of IVF?
In assisted reproductive technology in Kyrgyzstan, PGT technology is not only used for disease prevention, but also a powerful tool to improve success rates.
Accurately removing abnormal embryos: Many seemingly well-developed embryos actually have chaotic internal chromosomes. Transplanting such embryos often leads to non implantation, biochemical pregnancy, or early miscarriage. PGT can accurately identify and eliminate them.
Improving the success rate of single transplantation: Data shows that the clinical pregnancy rate can be significantly improved by transferring whole embryos that have undergone PGT screening, greatly reducing the economic and psychological burden caused by repeated transplantation failures.
Realizing eugenics: For couples with a family history of genetic diseases, PGT is the only effective way to block intergenerational transmission of diseases and ensure that the baby is born healthy.
Q3: What is the PGT operation process in Kyrgyzstan?
At the Tulip International Reproductive Center, the PGT process is rigorous and standardized to ensure the accuracy of every step.
Promotion of ovulation and egg retrieval: Doctors develop personalized plans based on the female's physical condition to obtain mature eggs.
Fertilization and blastocyst rearing: Fertilization is achieved using ICSI (intracytoplasmic sperm injection) technology, and the embryo is cultured in the laboratory until the blastocyst stage.
Biopsy and freezing: Embryologists perform biopsy sampling on blastocysts, followed by cryopreservation (vitrification technique), and wait for test results.
Gene sequencing and analysis: The samples are sent to the genetics laboratory for in-depth analysis using NGS (high-throughput sequencing) technology.
Report interpretation and transplantation: A detailed report will be issued in about 2-3 weeks. Doctors communicate with couples to select healthy blastocysts for thawing and transplantation.
Q4: Common genetic disease screening checklist: Which diseases can be blocked?
PGT technology can cover a wide range of diseases:
Chromosomal abnormalities:
Down syndrome (trisomy 21)
Edwards syndrome (trisomy 18)
Patao syndrome (trisomy 13)
Turner syndrome (sex chromosome abnormality)
Single gene genetic diseases (requiring customized probes):
Mediterranean anemia (alpha or beta)
Spinal muscular atrophy (SMA)
polycystic kidney
hemophilia
hereditary deafness
Q5: How do carriers of thalassemia welcome healthy babies?
Background of the case: Both L couple are carriers of the alpha thalassemia gene (mild). There is a 25% chance of natural conception giving birth to a child with severe thalassemia (Pap edema), which usually leads to stillbirth or neonatal death. They had experienced a painful mid-term induced abortion, both physically and mentally exhausted.
Solution: L couple contacted Tulip International Reproductive Center and decided to go to Kyrgyzstan for assisted reproduction.
Treatment process:
Genetic pre experiment: The medical team first collected blood samples from the couple and constructed exclusive family genetic haplotypes (pre experiment) to ensure the accuracy of the testing.
Promotion and retrieval of blastocysts: Ms. L obtained 6 high-quality blastocysts after one cycle of promotion and retrieval.
PGT-M testing: The laboratory conducted targeted thalassemia gene testing on these 6 blastocysts.
The results were revealed: the report showed that one embryo was severely diseased, three were carriers (healthy but carrying genes), and two were healthy embryos that did not carry any pathogenic genes at all.
The doctor transplanted one of the completely healthy embryos. Ten months later, a healthy baby was successfully born. After umbilical cord blood re examination, the baby does not carry the thalassemia gene at all.
Although genetic screening technology cannot solve all unknown medical problems, it is undoubtedly the most powerful "gatekeeper" in modern reproductive medicine. In Kyrgyzstan, the Tulip International Reproductive Center is using this technology to help countless families overcome genetic barriers and embrace healthy new life.
For fertility consultation in Kyrgyzstan, please contact your dedicated consultant
/Fertility Consultation /
Dr.Chan
Copy and add: Tulip_EnoChan
Or long press/scan the QR code to add
Tulip International Fertility Center
Technology aids fertility, fulfilling dreams for countless families
